Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy

Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy

Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the ‘mixed responses’ frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respo...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Willemsen, J. Bulgarelli, S.K. Chauhan, R.R. Lereim, D. Angeli, G. Grisendi, G. Krebbers, I. Davidson, J.A. Kyte, M. Guidoboni, R.M. Luiten, W.J. Bakker
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Immuno-Oncology and Technology
Subjects:
melanoma
AXL
MITF
DC vaccination
immune checkpoint
tumor heterogeneity
Online Access:http://www.sciencedirect.com/science/article/pii/S259001882400306X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items